Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20821278 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL18823182 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL21944186 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL8392554 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL10451694 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL24733023 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL18430894 | 1.00 | SIGMAR1 (0.81) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| Hydrochloric Acid SCHEMBL1356286 | 0.97 | SIGMAR1 (0.77) | SIGMAR1CYP1A2RAD52POLBMETAP1 | |
| SCHEMBL734010 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL7027757 | 0.94 | SIGMAR1 (0.73) | SIGMAR1CYP1A2RAD52POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478436-B | Multilayer composite polyimide material, and preparation method and application thereof | 广东粤港澳大湾区黄埔材料研究院 | 2025-01-24 | — | — | CN | claimed |
| CN-118307416-A | Method for synthesizing special amine compound by one-step method | 中海油天津化工研究设计院有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-116478436-A | Multilayer composite polyimide material, and preparation method and application thereof | 广东粤港澳大湾区黄埔材料研究院 | 2023-07-25 | — | — | CN | claimed |
| CN-113993511-A | Methods and formulations for treating visual disorders | 杰尼视界公司 | 2022-01-28 | — | — | CN | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| CN-102741269-A | Gadd45beta targeting agents | IMP INNOVATIONS LTD | 2012-10-17 | — | — | CN | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0443560-A2 | HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0041371-B1 | MELT-PROCESSABLE COPOLYAMIDES HAVING AROMATIC AMIDE UNIT AND FIBERS PREPARED THEREFROM | UNITIKA LTD. (JP) | 1986-08-06 | — | — | EP | claimed |
| US-4423263-A | REACTION WITH N-HALOGENAMINE IN PRESENCE OF PROTON DONOR AND METAL CATALYSTS | ANIC, S.P.A. (IT) | 1983-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | SIGMAR1 153/4885CYP1A2 257/4885RAD52 2581/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | SIGMAR1 125/4885CYP1A2 296/4885RAD52 3187/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | SIGMAR1 4339/4885CYP1A2 4371/4885RAD52 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.